because of the increased rate of relapse , the use of h2-receptor antagonist drugs as first-line intermittent healing therapy can be shown to be associated with an eight-fold ( 800 % ) increase in cost of pharmaceutical agents as compared with first-line treatment with bismuth salts ;
C0019593
h2-receptor antagonist drugs
C1254351
pharmaceutical agents